We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Topical and Intralesional Immunotherapy for the Management of Basal Cell Carcinoma.
- Authors
Fernández-Galván, Aurora; Rodríguez-Jiménez, Pedro; González-Sixto, Beatriz; Abalde-Pintos, María Teresa; Butrón-Bris, Beatriz
- Abstract
Simple Summary: Basal Cell Carcinoma is the most prevalent cancer in the white population, with a 30% lifetime risk for individuals with fair skin. The main treatment goal is to completely remove the tumor while preserving function and appearance. Surgery is usually the preferred method due to its high success rates and the ability to verify that the entire tumor has been excised. However, topical and intralesional immunotherapy, although traditionally secondary to surgery, have demonstrated effectiveness and good cosmetic outcomes. These non-surgical treatments are valuable alternatives for patients who cannot undergo surgery. The objectives of this review are to summarize the current state of topical and intralesional immunotherapy treatments for BCC and to evaluate their potential as effective alternatives for certain patient populations. Basal Cell Carcinoma (BCC) is the most common type of cancer among the white population. Individuals with fair skin have an average lifetime risk of around 30% for developing BCC, and there is a noticeable upward trend in its incidence rate. The principal treatment objectives for BCC involve achieving the total excision of the tumor while maximizing the preservation of function and cosmesis. Surgery is considered the treatment of choice for BCC for two main reasons: it allows for the highest cure rates and facilitates histological control of resection margins. However, in the subgroup of patients with low-risk recurrence or medical contraindications for surgery, new non-surgical treatment alternatives can provide an excellent oncological and cosmetic outcome. An evident and justified instance of these local therapies occurred during the COVID-19 pandemic, a period when surgical interventions carried out in hospital settings were not a viable option.
- Subjects
THERAPEUTIC use of antineoplastic agents; BASAL cell carcinoma treatment; CUTANEOUS therapeutics; SKIN tumors; IMMUNOTHERAPY; TREATMENT effectiveness; INJECTIONS; ALTERNATIVE medicine; IMMUNOMODULATORS; EVALUATION
- Publication
Cancers, 2024, Vol 16, Issue 11, p2135
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16112135